These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2004-004309-69 A randomized phase II study of gemcitabine/cisplatin with or without Cetuximab to evaluate the efficacy in patients with locally advanced or metastatic EGFR-positive pancreatic cancer. SpaCe TRIAL. bad-data
Ongoing 2007-000354-31 A randomized trial investigating the role of FOLFOX-4 regimen duration (3 versus 6 months) and bevacizumab as adjuvant therapy for patients with stage II/III colon cancer not-yet-due
Completed, but no date 2007-001781-32 A randomized phase II study of gemcitabine/cisplatin with or without sorafenib to evaluate the efficacy and safety in patients with locally advanced or metastatic pancreatic cancer. MAPS trial bad-data
Ongoing 2007-006254-26 Open-label randomized, parallel group, phase III, multicenter trial comparing two different sequences of therapy (irinotecan/cetuximab followed by fluorouracil/leucovorin with oxaliplatin ... not-yet-due
Completed, but no date 2008-004637-16 Folfiri as Second-Line chemotherapy for Advanced Pancreatic cancer: a GISCAD Phase II study FOLFIRI come trattamento di seconda linea nel carcinoma del pancreas avanzato. Studio di Fase II della ... bad-data
Completed, but no date, and reported results Terminated 2011-005537-39 A Randomized Phase III Study Of Low-Docetaxel Oxaliplatin, Capecitabine (Low-Tox) Vs Epirubicin, Oxaliplatin And Capecitabine (Eox) In Patients With Locally Advanced Unresectable Or Metastatic Gastric... bad-data
Ongoing 2012-005048-46 First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH FOLFIRI e bevacizumab nel trattamento di prima linea in pazienti con c... not-yet-due
Ongoing 2013-002973-23 A Phase II randomized trial comparing a combination of Abraxane and Gemcitabine versus Gemcitabine alone as first line treatment in locally advanced unresectable pancreatic cancer. Studio clinico d... not-yet-due
Ongoing 2017-002219-33 seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status seconD-line folfiri/aflIbercept in proSpe... not-yet-due
Ongoing 2020-003080-26 A randomized phase II trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC). Studio randomizza... not-yet-due